Extended indication Cipepofol monotherapy for treatment of general anaesthetic induction in adults and elderly undergoing elective surgery requiring endotracheal intubation
Total cost 27,500.00
Registration phase Clinical trials

Product

Active substance Cipepofol
Domain Neurological disorders
Reason of inclusion New medicine (specialité)
Main indication Pain
Extended indication Cipepofol monotherapy for treatment of general anaesthetic induction in adults and elderly undergoing elective surgery requiring endotracheal intubation
Manufacturer Haisco
Portfolio holder Haisco
Route of administration Intravenous
Therapeutical formulation Injection
Budgetting framework Intermural (MSZ)
Additional remarks Anestheticum. Fabrikant: Haisco Pharmaceutical

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Submission date June 2026
Expected Registration July 2027
Orphan drug No
Registration phase Clinical trials

Therapeutic value

Current treatment options Propofol
References NCT05486416 (HSK3486-309)

Expected patient volume per year

Patient volume 500 - 600

Market share is generally not included unless otherwise stated.

References Declaratiedata
Additional remarks Er zijn tussen de 500 en 600 jaarlijkse gebruikers van propofol.

Expected cost per patient per year

Cost 0.00 - 100.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

References Declaratiedata
Additional remarks Er wordt tussen de €20 en €40 per gebruiker propofol gedeclareerd.

Potential total cost per year

Total cost 27,500.00

Off label use

Indication extension

Other information